Therapeutic Peptide Oral Delivery

Oral delivery of therapeutic peptides remains one of the greatest challenges in drug development. The gastrointestinal (GI) tract presents multiple barriers that peptides must overcome to reach systemic circulation.

Challenges of Oral Peptide Delivery

Peptides face several obstacles in the GI tract:

1. Enzymatic degradation: Proteases in the stomach and intestine break down peptides
2. Poor permeability: Large molecular size and hydrophilicity limit membrane crossing
3. Unfavorable pH: Gastric acid can denature and degrade peptides
4. Efflux mechanisms: P-glycoprotein pumps peptides back into the lumen
5. Mucus barrier: Thick mucus layer limits access to absorptive cells

Permeation Enhancers

Permeation enhancers increase paracellular or transcellular transport of peptides across the intestinal epithelium:

Tight junction modulators:

• Zonula occludens toxin (ZOT): Reversibly opens tight junctions
• Chitosan and derivatives: Mucoadhesive, opens tight junctions
• EDTA: Chelates calcium, disrupts tight junctions

Transcellular enhancers:

• Bile salts: Disrupt cell membranes, increase fluidity
• Fatty acids: Form micelles, enhance absorption
• Surfactants: Increase membrane permeability

Safety considerations:

• Must be reversible to avoid permanent damage
• Should not cause irritation or inflammation
• Need to balance efficacy with safety profiles

Enzyme Inhibitors

Enzyme inhibitors protect peptides from degradation in the GI tract:

Protease inhibitors:

• Aprotinin: Serine protease inhibitor
• Bacitracin: Broad-spectrum protease inhibitor
• Bestatin: Aminopeptidase inhibitor
• Captopril: ACE inhibitor for specific peptides

Formulation strategies:

• Co-formulation with the peptide drug
• Enteric coating to prevent premature release
• Targeted delivery to sites of lower enzyme activity

Nanoparticle Encapsulation

Nanoparticles protect peptides and enhance their absorption:

Types of nanoparticles:

• Polymeric: PLGA, chitosan, albumin-based
• Lipid-based: Liposomes, solid lipid nanoparticles
• Inorganic: Gold, silica (less common for oral delivery)

Mechanisms of enhancement:

• Protection: Encapsulation shields peptides from enzymes
• Mucoadhesion: Nanoparticles adhere to mucus layer
• Transcytosis: Cellular uptake via endocytosis
• Controlled release: Sustained peptide delivery

Surface modification:

• PEGylation for stealth properties
• Targeting ligands for specific uptake
• Charge optimization for mucoadhesion

Clinical Applications

Current oral peptide drugs and technologies:

• Oral insulin: Various formulations in development
• Oral GLP-1 agonists: Some approved for diabetes
• Oral calcitonin: For osteoporosis treatment
• Oral cyclosporine: Immunosuppressant with absorption enhancers

Practical Learning Tip

Mnemonic: “PEN for Oral Delivery” - Remember the three main strategies: Permeation enhancers, Enzyme inhibitors, Nanoparticles. These work together to overcome the barriers of oral peptide delivery.

Future Directions

Emerging approaches include:

• Cell-penetrating peptides: Enhanced cellular uptake
• Microbiome-based delivery: Using gut bacteria for protection
• Smart materials: pH or enzyme-responsive release
• Combination strategies: Multiple approaches for synergistic effects

Understanding these delivery strategies is essential for developing effective oral peptide therapeutics that can improve patient compliance and therapeutic outcomes.